News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Panel to Review Genentech, Inc.'s (Jobs) Avastin for Breast Cancer
September 14, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LOS ANGELES, Sept 13 (Reuters) - Genentech Inc.'s blockbuster drug Avastin will be reviewed as a first-line treatment for metastatic breast cancer by a U.S. Food and Drug Administration advisory panel in December, the company said on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Genentech, Inc.
MORE ON THIS TOPIC
Approvals
Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders
July 2, 2026
·
2 min read
·
Tristan Manalac
Approvals
Orca opens up Treg cell therapy with FDA nod for allogeneic blood cancer treatment
July 1, 2026
·
2 min read
·
Heather McKenzie
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
·
2 min read
·
Nick Paul Taylor
Duchenne muscular dystrophy
Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail
July 1, 2026
·
2 min read
·
Tristan Manalac
